Prime Medicine
Founded Year
2019Stage
IPO | IPOTotal Raised
$315MDate of IPO
10/20/2022Market Cap
0.64BStock Price
6.60About Prime Medicine
Prime Medicine (NASDAQ: PRME) operates as a biotechnology company involved in gene editing for patients. It offers prime editing, a technology that can search and replace to restore normal gene function anywhere in the genome. The technology finds the precise place in the genome to edit and replaces the segment of faulty deoxyribonucleic acid (DNA) with a correct copy of DNA. The company was founded in 2019 and is based in Cambridge, Massachusetts.
Loading...
Loading...
Research containing Prime Medicine
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Prime Medicine in 3 CB Insights research briefs, most recently on Jul 14, 2023.
Expert Collections containing Prime Medicine
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Prime Medicine is included in 1 Expert Collection, including Synthetic Biology.
Synthetic Biology
238 items
Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.
Prime Medicine Patents
Prime Medicine has filed 1 patent.
The 3 most popular patent topics include:
- biotechnology
- gene expression
- molecular biology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
6/15/2022 | Molecular biology, Transcription factors, Biotechnology, Molecular biology techniques, Gene expression | Application |
Application Date | 6/15/2022 |
|---|---|
Grant Date | |
Title | |
Related Topics | Molecular biology, Transcription factors, Biotechnology, Molecular biology techniques, Gene expression |
Status | Application |
Latest Prime Medicine News
Nov 8, 2023
November 08, 2023 08:00 ET Cambridge, Massachusetts, UNITED STATES Cambridge, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today announced that company management will present at two upcoming investor conferences: Stifel Healthcare Conference: Fireside Chat by Keith Gottesdiener, M.D., President and Chief Executive Officer, on Tuesday, November 14, 2023, at 4:10 p.m. Jefferies London Healthcare Conference: Fireside Chat by Jeremy Duffield, M.D., Ph.D., Chief Scientific Officer, on Thursday, November 16, 2023, at 1:30 p.m. GMT (8:30 a.m. Live audio webcasts of both presentations will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com . Replays of each webcast will be available on the Prime Medicine website for 30 days following each presentation. About Prime Medicine Prime Medicine is a leading biotechnology Company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is leveraging its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated, one-time, potentially curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Prime Medicine is currently progressing a diversified portfolio of eighteen programs initially focused on genetic diseases with a fast, direct path to treating patients or with a high unmet need because they cannot be treated using other gene-editing approaches. Over time, the Company intends to maximize Prime Editing’s therapeutic potential and advance potentially curative therapeutic options to patients for a broad spectrum of diseases. For more information, please visit www.primemedicine.com . © 2023 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners. Investor Contact
Prime Medicine Frequently Asked Questions (FAQ)
When was Prime Medicine founded?
Prime Medicine was founded in 2019.
Where is Prime Medicine's headquarters?
Prime Medicine's headquarters is located at 21 Erie Street, Cambridge.
What is Prime Medicine's latest funding round?
Prime Medicine's latest funding round is IPO.
How much did Prime Medicine raise?
Prime Medicine raised a total of $315M.
Who are the investors of Prime Medicine?
Investors of Prime Medicine include ARCH Venture Partners, F-Prime Capital, Newpath Partners, Google Ventures, T. Rowe Price and 8 more.
Loading...
Loading...